GLP-1 medications like semaglutide and tirzepatide have become widely known for their effects on weight loss and blood sugar control. But new research suggests their impact may extend further, and that those benefits may not last if treatment is interrupted.
In a study of more than 333,000 U.S. adults with type 2 diabetes, researchers found that people who stopped taking GLP-1 medications had a higher risk of heart attack, stroke, and death compared with those who continued treatment. Even temporary interruptions were linked to reduced protection.
“There is enormous exuberance about starting GLP-1 drugs, but not nearly enough attention to what happens when people stop,” said Dr. Ziyad Al-Aly, a clinical epidemiologist at Washington University in St. Louis and the study’s senior author.
The analysis, published in BMJ Medicine, followed patients for up to three years and compared those taking GLP-1 medications with those using older diabetes treatments. People who stayed on GLP-1 drugs continuously had the greatest reduction in cardiovascular risk. Those who stopped saw that benefit shrink over time, with longer gaps in treatment tied to larger increases in risk.
Weight regain is often the most noticeable change when people stop these medications, but the researchers found that less visible shifts may be happening as well. Blood pressure, cholesterol, and inflammation levels can begin to move in the opposite direction once treatment is interrupted.
“Weight regain is visible; the metabolic reversal is not,” Al-Aly said.
The study also found that restarting treatment helped restore some of the lost benefit, but not completely. Participants who interrupted therapy and later resumed still had higher risk compared with those who stayed on the medication continuously.
“Our data suggest this metabolic whiplash is detrimental to heart health,” Al-Aly said.
These findings reflect how GLP-1 medications work in the body. Rather than permanently changing metabolism, they help regulate appetite, insulin response, and energy balance while they are being used. When the medication is removed, the body often shifts back toward its previous state.
That pattern is not unique to medications. In nutrition and metabolic health more broadly, maintaining changes over time is often what determines long-term outcomes. Initial improvements can fade if the underlying drivers of weight and metabolism are no longer being influenced.
The study also highlights a practical challenge. Many people do not stay on GLP-1 medications long term, often due to cost, side effects, or limited access. In this analysis, a substantial portion of patients either stopped treatment or had gaps of six months or more.
The results do not suggest that GLP-1 medications are necessary or appropriate for everyone. But they do reinforce that these drugs are treating ongoing conditions rather than offering a short-term reset. For people who start them, what happens after the first few months may matter just as much as the initial response.
This study was conducted by researchers at Washington University in St. Louis using data from U.S. veterans and was funded by the U.S. Department of Veterans Affairs. The funders had no role in the study’s design, analysis, or reporting.